SEC Tracker
Get the app

Denali Therapeutics DNLI

Schenkein David (Director) plans to sell 59,441 DNLI shares, about $1.9M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Nov 11, 2024
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Exercise of Stock Options; Restricted Stock Units
  4. 10b5-1 plan adopted: Aug 12, 2024

All of Schenkein David's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 27,129 shares at $32.09 on Nov 11, 2024 · Form 4
  • Sold 32,312 shares at $32.87 on Nov 11, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Denali Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
  2. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  3. Mannkind MNKD public float $1.1B, Jun 30, 2025
  4. Novavax NVAX public float $1.0B, Jun 30, 2025
  5. Harrow HROW public float $1.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.